Objective:To study the change of serum tumor markers and lesion cancer cell proliferation gene expression after Nimotuzumab combined with cisplatin and radiotherapy treatment of middle-advanced cervical cancer.Methods...Objective:To study the change of serum tumor markers and lesion cancer cell proliferation gene expression after Nimotuzumab combined with cisplatin and radiotherapy treatment of middle-advanced cervical cancer.Methods:A total of 78 patients with middle-advanced cervical cancer who were treated in our hospital between August 2013 and February 2016 were collected and divided into the control group (n=39) who received routine radiotherapy and chemotherapy and the observation group (n=39) who received Nimotuzumab combined with cisplatin and radiotherapy according to the single-blind randomized control method, and both groups were treated for 6 weeks. Before treatment and after 6 weeks of treatment, enzyme-linked immunosorbent assay (ELISA) was used to detect serum tumor marker levels, and fluorescence quantitative PCR method was used to detect the lesion proliferation gene mRNA expression.Results: Before treatment, the differences in serum tumor marker levels and lesion proliferation gene mRNA expression were not statistically significant between two groups of group. After 6 weeks of treatment, serum tumor markers SCC, CA125 and CA19-9 levels of observation group were lower than those of control group, lesion pro-proliferation genes B7-H4, HIF-1α, Sp2 and PCNA mRNA expression were lower than those of control group, and lesion anti-proliferation genes PTEN, FHIT and STC1 mRNA expression were higher than those of control group.Conclusion: Nimotuzumab combined with cisplatin and radiotherapy can effectively reduce the serum tumor marker levels, and also inhibit the lesion cancer cell proliferation in patients with middle-advanced cervical cancer.展开更多
文摘Objective:To study the change of serum tumor markers and lesion cancer cell proliferation gene expression after Nimotuzumab combined with cisplatin and radiotherapy treatment of middle-advanced cervical cancer.Methods:A total of 78 patients with middle-advanced cervical cancer who were treated in our hospital between August 2013 and February 2016 were collected and divided into the control group (n=39) who received routine radiotherapy and chemotherapy and the observation group (n=39) who received Nimotuzumab combined with cisplatin and radiotherapy according to the single-blind randomized control method, and both groups were treated for 6 weeks. Before treatment and after 6 weeks of treatment, enzyme-linked immunosorbent assay (ELISA) was used to detect serum tumor marker levels, and fluorescence quantitative PCR method was used to detect the lesion proliferation gene mRNA expression.Results: Before treatment, the differences in serum tumor marker levels and lesion proliferation gene mRNA expression were not statistically significant between two groups of group. After 6 weeks of treatment, serum tumor markers SCC, CA125 and CA19-9 levels of observation group were lower than those of control group, lesion pro-proliferation genes B7-H4, HIF-1α, Sp2 and PCNA mRNA expression were lower than those of control group, and lesion anti-proliferation genes PTEN, FHIT and STC1 mRNA expression were higher than those of control group.Conclusion: Nimotuzumab combined with cisplatin and radiotherapy can effectively reduce the serum tumor marker levels, and also inhibit the lesion cancer cell proliferation in patients with middle-advanced cervical cancer.
